Meiji Seika Pharma 20150121 .ppt [互換モード] · • Meiji Seika Pharma Co., Ltd. ... Bacterial Pneumonia; ... Meiji Seika Pharma 20150121 .ppt [互換モード] Author: MS10068

• Meiji Group Overview• Meiji Seika Pharma Co., Ltd.

Last updated January 21, 2015 2

◆Meiji Group

Ethical Pharmaceutical Business

Agricultural Chemicals and Veterinary Drugs Business

Unit for Confectionary Business

Unit for Dairy Products Business

Unit for Healthcare and Nutrition Business

Unit for International Business

Consolidated Sales$11.5B (Apr. 2013 – Mar. 2014)Consolidated Number of Employees14,819 (as of March 31st, 2014)

Last updated January 21, 2015 3

Consolidated Sales Operating Incomes

* Growth vs. previous business year1USD=100JPY

Based on the sales before intergroup eliminationApr. 2013 - Mar. 2014

R&D Expenditure

$364M(+41.1% *)

$11.5B(+1.9% *)

$260M

◆Financial Overview

Last updated January 21, 2015 4

• Meiji Group Overview• Meiji Seika Pharma Co., Ltd.

Last updated January 21, 2015 5

R&D Administration

Intellectual Property

D. KobayashiPresident & Representative Director

Marketing Div.Y. Umeki, Managing Executive Officer

Generics Development

Bioscience Labs.

HR & General Affairs

Financial & Accounting

Audit

Drug Information Center

Executive Committee

Partnering Strategy and Business Development

◆Organization  

Consolidated Number of Employees : 4,035 (As of April, 2014)

Last updated January 21, 2015

Production Div.T. Nagasato, Executive Officer

International HeadquartersK. Noda, Executive Officer

External Affairs

Pharmaceutical Research Div.T. Kikkoji, Executive Officer

Reliability & Quality Assurance CenterK. Mori, General Manager

Agricultural & Veterinary Div.S. Hashimoto, Executive Officer

Pharmaceutical Development Div.H. Yamaguchi, Managing Executive Officer

Corporate Development

Research Planning

6

Corporate DevelopmentGeneral Manager： Dr. Hiromasa Takizawa

Licensing and Alliance ManagementGroup Manager : Mr. Toru Kawahatsu

Managing Executive Officer: Mr. Yuji Sasaki

Partnering Strategy and Business DevelopmentGeneral Manager：Mr. Kenshi Murase

Task : Product In-Licensing, Alliance ManagementProduct Out-Licensing

◆Business Development & Licensing 

Last updated January 21, 2015

Licensing and Product AcquisitionGroup Manager : Mr. Kazuyoshi Kataha

Task : Alliance Management, Agro-Vet LicensingGeneric Product Licensing, R&D Contract

7

Employees (As of October, 2014)12 Branches and 72 Sales Offices (10 CNS Sales Offices)

MR  ca. 810(CNS specialized MR ca. 200 )R&D                ca. 360

Headquarters (Kyobashi Tokyo)‐ Domestic Marketing Div.‐ Production Div.‐ International Div.‐ Reliability & QA Center‐ R&D Div.

Pharmaceutical Research Center &CMC Labs. (Yokohama)

Bioscience Labs.(Ashigara)   

Odawara Plant (Drug Formulation)

Kitakami Plant (API)Gifu Plant (API)

Group companies・Ohkura PharmaceuticalManufacturing & sales of ethical pharmaceuticals and diagnostics

・Kitasato Pharmaceutical IndustrySales of ethical vaccines

Ohkura Pharmaceutical (Kyoto)

Kitasato Pharmaceutical Industry (Tokyo)

◆Business Locations : Japan

Last updated January 21, 2015 8

Beijing Office

Shantou Meiji Pharmaceuticals Co., Ltd. (1989)

Production & Distribution

P.T. Meiji IndonesianPharmaceutical Industries (1974)Production, Distribution & Export

Thai Meiji Pharmaceutical Co., Ltd. (1979)Production, Distribution & ExportTedec‐Meiji 

Farma, S.A. (1991)Production, Distribution & Export

Los Angeles Office

Meiji Pharma (Shandong)  Co., Ltd. (2004)

Fermentation Production

DM Bio Limited. (2013)

Monoclonal Antibody Production

Meiji Pharma Korea Co., Ltd. (2012)

Distribution (Agrochemicals)

◆Business Locations : World

Last updated January 21, 2015 9

Consolidated basis$1,351M (+6.1% *)

Ethical Pharmaceuticals$1,135M 

‐ domestic sales‐ overseas sales‐ export

Agrochemicals & Animal Health$215M

84%

16%

◆Segment Sales

* Growth vs. previous business year1USD=100JPY

Apr. 2013 - Mar. 2014

Last updated January 21, 2015 10

Ethical Pharmaceutical Sales /Japan(Apr.2012‐Mar.2013)

Meiact®Fosmicin®Isodine®Habekacin®Omegacin®Orapenem ®

Sword®

Meilax® (Ethyl Loflazepate) : AnxietyDepromel®  (Fluvoxamine) : Depression, OCD, SADReflex® (Mirtazapine) : DepressionDiacomit ®(Stiripentol) : Antiepileptic

Ebastel® (Ebastin): Urticaria, RhinitisDaunomycin ® : Acute LeukemiaTherarubicin® (Pirarubicin) : Malignant LymphomaLaserphyrin ® (Talaporfin Sodium ): Lung Carcinoma, Brain TumorOxis® 9µg Turbuhaler® (Formoterol) : COPD

Infection (29%)$266M

CNS (26%)$239M

Others (9%)$85M

Generics (35%)$321M

Total$911M

◆Sales by Therapeutic Area

Last updated January 21, 2015 11

* NaSSA : Noradrenergic and Specific Serotonergic Antidepressant

◆Leading ProductsBrand Name(Date of Launch)

MOA/Indication Sales in Japan Partner

Reflex (’09.9) NaSSA* : Depression $167M   MSD

Meiact (’94.6) Oral cephem $162M  

Amlodipine (’08.7) Ca antagonist $43M   

Depromel (’99.5) SSRI: Depression, OCD, SAD $40M     AbbVie

Vancomycin MEEK (’02.7) Glycopeptide: MRSA $37M     Kobayashi Kako

Meilax (’88.12) Benzodiazepine: Anxiety $31M    Sanofi

Fosmicin (’80.12) Fosfomycin $30M   

Sulbacillin (’06.9) Penicillin $29M    

Donepezil (’11.11) Anti‐Alzheimer’s disease $26M  

Orapenem (’09.8) Oral Carbapenem $23M     Pfizer

Isodine (’61.11) Anti‐septic $19M     Mundipharma

Ebastel (’96.6) H1antagonist: Urticaria, Rhinitis $14M     Dainippon Sumitomo

Omegacin (’02.3)  Carbapenem $12M     Pfizer

Habekacin (’90.12) Aminoglycoside: MRSA $10M    

Ethical Pharmaceutical Sales /Japan(Apr.2013‐Mar.2014)

Last updated January 21, 2015 12

◆Product Pipeline : Infectious Diseases

Compound MOA Indication Status Partner Territory

ME1111 Antifungal Onychomycosis <US>Phase II

Global

ME1100(Arbekacin)

Aminoglycoside(Inhalation)

Hospital Acquired Bacterial Pneumonia;Ventilator Associated Bacterial Pneumonia

<US>Phase I

PARI Pharma Global

OP0595 β‐lactamase inhibitor

Bacterial Infection <Australia>Phase I

Roche Japan

Last updated January 21, 2015 13

◆Product Pipeline : CNS Diseases

Compound MOA Indication Status Partner Territory

ME2136(Asenapine)

SDA Schizophrenia Phase III MSD(in‐license)

Japan

Depromel(Fluvoxamine)

SSRI Obsessive Compulsive Disorder (Pediatric)

Phase IIILine Extension

AbbVie(in‐license)

Japan

ME2112(Ziprasidone)

SDA Schizophrenia Phase II RaQualia(in‐license)

Japan

Reflex(Mirtazapine)

NaSSA Fibromyalgia Phase IILine Extension

MSD(in‐license)

Japan

ME2125(Safinamide)

MAO‐Binhibitor

Parkinson’s Disease Phase I Newron(in‐license)

Asia

Last updated January 21, 2015 14

◆Product Pipeline : New Fields

Compound MOA Indication Status Partner Territory

ME2906(Talaporfin)

Photosensitizer

Esophagus Cancer Filed Japan

ME3113(Udenafil)

PDE‐Vinhibitor

Benign Prostatic Hyperplasia

Phase IIb Dong‐A ST(in‐license)

Japan

DMB‐3111(Herceptin)

MonoclonalAntibody(Biosimilar)

Breast Cancer Phase I Dong‐A Socio(Researchcollaboration)

Darinaparsin Mitochondrial‐targeted agent

Relapsed and Refractory  PTCL*

Phase I SolasiaPharma(in‐license)

Japan

Last updated January 21, 2015

* PTCL: Peripheral T‐Cell Lymphoma

15

◆Out‐Licensing Activities

Compound MOA Indication Status Partner Territory

OP0595 β‐lactamase inhibitor

Bacterial Infection Phase I Roche Global(exc. JP)

LS11(ME2906; Talaporfin)

PhotosensitizerHepatocellular CarcinomaMetastatic Colorectal CancerBenign Prostatic Hyperplasia

Phase IIIPhase IIPhase I

Light SciencesOncology

Global(exc. JP)

ME3301 Anti‐inflammatory

IBD, Allergic Rhinitis Phase II Amalyte Global

CP8816 &CP8863

Progesterone receptor modulator

Endometriosis Pre‐clinical

Tokai Global

MN‐447(CP4715)

GpⅡbⅢa & αγβ3 receptor dual antagonist

Acute Ischemic Heart DiseaseCerebral Infarction

Pre‐clinical

MediciNova

Global

Last updated January 21, 2015 16

◆Recent Alliance DealsMon./Year Partner Type of Collaboration

Jan. 2015 Solasia Pharma Commercialization partnership of Darinaparsin / PTCL in Japan

Jan. 2015 Roche   License Agreement regarding OP0595 / beta‐lactamase Inhibitor 

Sep. 2014 Takeda Co‐Promotion partnership of Ramelteon / Insomnia in Japan

Jul. 2014 Ono Pharmaceutical

Development and Commercialization partnership of Limaprost alfadex in Thailand and Indonesia

Jul. 2013 PARI Pharma In‐license of eFlow® Technology inhalation device for ME1100

Apr. 2013 MSD In‐license of Asenapine / Schizophrenia in Japan

Oct. 2012 OHKURA Distribution of Check hMPV / Diagnostic reagent kit in Japan

May 2012 AstraZeneca Distribution of Oxis® 9µg Turbuhaler® 28doses / COPD in Japan

May 2012 OHKURA Distribution of Check AD / Diagnostic reagent kit in Japan

Apr. 2012 R‐Pharm Out‐license and Distribution partnership of MEIACT MS® and ADANT® in Russia

Apr. 2012 Thien Thao Distribution partnership of Meiji products in Viet Nam

Jan. 2012 Newron In‐license of Safinamide / Parkinson’s Disease In Asia

Dec. 2011 OHKURA Distribution of Check RSV/ Diagnostic reagent kit in JapanLast updated January 21, 2015 17

◆In‐licensing fields  

Marketing Collaboration• ENT• Pediatric• Respiratory• Psychiatry & Neurology• Hematology

Research Collaboration• Infectious Diseases• Inflammatory Diseases• Unmet Medical Needs

Last updated January 21, 2015 18

◆Current Partnerships  

Last updated January 21, 2015 19

Last updated January 21, 2015 20